Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

Published 20/05/2022, 15:02
© Reuters.  ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China
CHNA
-
VENM
-

  • ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited.
  • ChromaDex Asia is expected to assume the distribution agreement with Sinopharm Xingsha relating to the commercialization of Tru Niagen in mainland China and its territories, excluding Hong Kong, Macau, and Taiwan.
  • Also See: ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements.
  • The JV's entry into a distribution agreement will be contingent upon Sinopharm successfully attaining health food product registration for Tru Niagen with the People's Republic of China's State Administration for Market Regulation.
  • True Niagen is a dietary supplement meant to reinvigorate cell growth and repair by raising NAD (nicotinamide adenine dinucleotide) levels in the body.
  • According to the company, raising NAD levels can turn back the clock on aging and improve virtually every aspect of one's health.
  • Price Action: CDXC shares are up 18.2% at $2.08 on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.